复方氨基酸胶囊治疗维持性血液透析患者营养不良及钙磷代谢障碍的有效性和安全性

吴望舒, 王旻洲, 宋阿会, 赵冰茹, 鲁嘉越, 洪文凯, 顾乐怡, 谢可炜, 陆任华

Efficacy and safety of compound amino acid capsules in the treatment of malnutrition and calcium and phosphorus metabolism disorders in maintenance hemodialysis patients

WU Wangshu, WANG Minzhou, SONG Ahui, ZHAO Bingru, LU Jiayue, HONG Wenkai, GU Leyi, XIE Kewei, LU Renhua

表1 2组一般资料比较

Tab 1 Comparison of general characteristics between the two groups

Item Treatment group (n=21) Control group (n=19) t/χ2/U value P value Age/year 64.67±10.75 59.37±12.78 1.424 0.163 Male/n(%) 14 (66.7) 16 (84.2%) 0.835① 0.361 Dialysis duration/month 29.1 (64.4) 34.9 (58.1) 181.000② 0.616 Baseline body mass index/(kg·m-2) 20.34±2.59 22.91±4.40 -1.251 0.219 Baseline Kt /V 1.60±0.40 1.57±0.26 0.211 0.834 Baseline ultrafiltration volume/mL 2 400.00±989.95 2 742.11±697.07 -1.273 0.211 Primary renal disease/n(%) 10.608① 0.035 Chronic glomerulonephritis 6 (28.6) 6 (31.6) Hypertensive nephrosclerosis 4 (20.0) 4 (21.1) Diabetic nephropathy 0 (0) 1 (5.3) Polycystic kidney 3 (7.5) 0 (0) Other 5 (12.5) 0 (0) Unknown causes 3 (27.5) 8 (42.1)